Context Therapeutics annual return on equity
2021
2022
2023
2024
2025
Context Therapeutics Return on Equity (ROE) Growth & History (CNTX)
Context Therapeutics's return on equity was −46.39% for fiscal 2025.
View full Context Therapeutics company overviewContext Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −46.39% | +3.50 pp |
| 2024 | 2024-12-31 | −49.89% | +52.90 pp |
| 2023 | 2023-12-31 | −102.79% | −67.05 pp |
| 2022 | 2022-12-31 | −35.74% | +30.97 pp |
| 2021 | 2021-12-31 | −66.71% | — |
Context Therapeutics quarterly return on equity
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −32.22% | −22.04 pp |
| Q1 2026 | 2026-03-31 | −15.41% | −10.49 pp |
| Q4 2025 | 2025-12-31 | −19.49% | −15.76 pp |
| Q3 2025 | 2025-09-30 | −12.45% | +6.43 pp |
| Q2 2025 | 2025-06-30 | −10.17% | −6.06 pp |
| Q1 2025 | 2025-03-31 | −4.92% | +31.20 pp |
| Q4 2024 | 2024-12-31 | −3.73% | +41.02 pp |
| Q3 2024 | 2024-09-30 | −18.88% | +8.84 pp |
| Q2 2024 | 2024-06-30 | −4.12% | +14.89 pp |
| Q1 2024 | 2024-03-31 | −36.11% | −16.24 pp |
| Q4 2023 | 2023-12-31 | −44.75% | −34.98 pp |
| Q3 2023 | 2023-09-30 | −27.72% | −18.05 pp |
| Q2 2023 | 2023-06-30 | −19.00% | −9.85 pp |
| Q1 2023 | 2023-03-31 | −19.87% | −12.53 pp |
| Q4 2022 | 2022-12-31 | −9.77% | +14.91 pp |
| Q3 2022 | 2022-09-30 | −9.67% | — |
| Q2 2022 | 2022-06-30 | −9.16% | — |
| Q1 2022 | 2022-03-31 | −7.34% | — |
| Q4 2021 | 2021-12-31 | −24.68% | — |
Context Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Context Therapeutics's return on equity increased from −66.71% to −46.39%, a change of +20.32 percentage points. The latest reported quarter, Q2 2026, shows −32.22%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Context Therapeutics source filings ↗